EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers

Karen M Tuesley iD, Katrina Spilsbury iD, Sallie-Anne Pearson iD, Peter Donovan iD, Andreas Obermair iD, Michael D Coory iD, Sitwat Ali iD, Nirmala Pandeya iD, Louise Stewart iD, Susan J Jordan iD, Penelope M Webb iD

JNCI: Journal of the National Cancer Institute · 2025

DOI: 10.1093/jnci/djae282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Karen M Tuesley und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, University of Queensland, Brisbane, QLD 4006, Australia. Hauptthemen laut MEDLINE: Breast Neoplasms, Genital Neoplasms, Female, Contraceptive Agents, Female, Progestins. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Use of long-acting, reversible contraceptives has increased over the past 20 years, but an understanding of how they could influence cancer risk is limited.

Methods

We conducted a nested case-control study among a national cohort of Australian women (n = 176 601 diagnosed with cancer between 2004 and 2013; 882 999 matched control individuals) to investigate the associations between the levonorgestrel intrauterine system, etonogestrel implants, depot-medroxyprogesterone acetate and cancer risk and compared these results with the oral contraceptive pill. We used conditional logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI).

Results

Levonorgestrel intrauterine system and etonogestrel implant use was associated with breast cancer risk (OR = 1.26, 95% CI = 1.21 to 1.31, and OR = 1.24, 95% CI = 1.17 to 1.32, respectively), but depot-medroxyprogesterone acetate was not, except when used for 5 or more years (OR = 1.23, 95% CI = 0.95 to 1.59). Reduced risks were seen for levonorgestrel intrauterine system (≥1 years of use) in endometrial cancer (OR = 0.80, 95% CI = 0.65 to 0.99), ovarian cancer (OR = 0.71, 95% CI = 0.57 to 0.88), and cervical cancer (OR = 0.62, 95% CI = 0.51 to 0.75); for etonogestrel implant in endometrial cancer (OR = 0.21, 95% CI = 0.13 to 0.34) and ovarian cancer (OR = 0.76, 95% CI = 0.57 to 1.02); and for depot-medroxyprogesterone acetate in endometrial cancer (OR = 0.21, 95% CI = 0.13 to 0.34). Although levonorgestrel intrauterine system, etonogestrel implant and depot-medroxyprogesterone acetate were all associated with increased cancer risk overall, for etonogestrel implant, the risk returned to baseline after cessation, similar to the oral contraceptive pill. We were unable to adjust for all potential confounders, but sensitivity analyses suggested that adjusting for parity, smoking, and obesity would not have materially changed our findings.

Conclusion

Long-acting, reversible contraceptives have similar cancer associations to the oral contraceptive pill (reduced endometrial and ovarian cancer risks and short-term increased breast cancer risk). This information may be helpful to women and their physicians when discussing contraception options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsGenital Neoplasms, FemaleContraceptive Agents, FemaleProgestinsHumansFemaleCase-Control StudiesAdultMiddle AgedLevonorgestrelMedroxyprogesterone AcetateAustraliaDesogestrelRisk FactorsAgedYoung AdultIntrauterine Devices, MedicatedOdds RatioDrug Implants

Substanzen

LevonorgestrelMedroxyprogesterone AcetateContraceptive Agents, FemaleDesogestrelProgestinsetonogestrelDrug Implants

Autor:innen und Institutionen

  • School of Public Health, University of Queensland, Brisbane, QLD 4006, Australia.
  • Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • Institute for Health Research, The University of Notre Dame Australia, Fremantle, WA 6160, Australia.
  • School of Population Health, University of New South Wales, Sydney, NSW 2052, Australia.
  • Centre of Research Excellence in Medicines Intelligence, University of New South Wales, Sydney, NSW 2052, Australia.
  • Clinical Pharmacology Department, Royal Brisbane and Women's Hospital, Brisbane, QLD 4006, Australia.

ORCID-Profile: Karen M Tuesley, Katrina Spilsbury, Sallie-Anne Pearson, Peter Donovan, Andreas Obermair, Michael D Coory, Sitwat Ali, Nirmala Pandeya, Louise Stewart, Susan J Jordan, Penelope M Webb

Förderung

  • Australian National Health and Medical Research Council

Zitieren

APA

Tuesley, K. M., Spilsbury, K., Pearson, S. A., Donovan, P., Obermair, A., Coory, M. D., Ali, S., Pandeya, N., Stewart, L., Jordan, S. J., & Webb, P. M. (2025). Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae282

Vancouver

Tuesley KM, Spilsbury K, Pearson SA, Donovan P, Obermair A, Coory MD, et al. Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djae282

BibTeX
@article{Tuesley2025,
  author = {Tuesley, Karen M and Spilsbury, Katrina and Pearson, Sallie-Anne and Donovan, Peter and Obermair, Andreas and Coory, Michael D and Ali, Sitwat and Pandeya, Nirmala and Stewart, Louise and Jordan, Susan J and Webb, Penelope M},
  title = {Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2025},
  doi = {10.1093/jnci/djae282}
}
Kostenlos starten →